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Summary
Objective: The characterization of macrolide resistance in Gram-positive cocci recovered from
Colombian hospitals.
Methods: The resistance profiles and mechanism of macrolide resistance were investigated in
isolates of Streptococcus pneumoniae (1679), Staphylococcus aureus (348), coagulase-negative
staphylococci (CoNS) (175), and Enterococcus spp (123). Minimum inhibitory concentrations
(MICs) for erythromycin (ERY) and clindamycin (CLI), detection of macrolide resistance genes,
phenotypic characterization, and pulsed field gel electrophoresis (PFGE) of macrolide-resistant
pneumococci were performed.
Results: Resistance to ERY and CLI was 3.3% and 2.3% for S. pneumoniae, 58% and 57% for S.
aureus (94% for both compounds in methicillin-resistant Staphylococcus aureus (MRSA)), and
78.6% and 60.7% in methicillin-resistant Staphylococcus epidermidis, respectively. ERY resistance
was 62% in Enterococcus faecalis and 82% in Enterococcus faecium. The MLSB-type accounted for
71% of S. pneumoniae and 100% of MRSA. The erm(A) gene was prevalent in MRSA, erm(B) in S.
pneumoniae and enterococci, and erm(C) in CoNS isolates. Efflux pump genes (mef(A) genes)
were mostly identified in S. pneumoniae (24%). The most common genotype amongst ERY-
resistant pneumococci was the Spain6B-2 clone.
Conclusions: The prevalence of macrolide resistance is low in Colombian pneumococci and high
in MRSA (cMLSB-type).
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Macrolide, lincosamide and streptogramin (MLSB) antibiotics
are chemically distinct compounds that share a similar mode
of action: they all bind to the large ribosomal subunit, close
to the peptidyl transferase center.1 This center is composed
entirely of RNA and catalyzes formation of peptide bonds
during protein elongation. Lincosamides and macrolides
that contain a mycarose sugar inhibit the peptidyl transfer-
ase reaction, having binding sites partly overlapping with
substrates of the enzyme. In contrast, macrolides of the
erythromycin group and streptogramin type B block the
entrance to the tunnel in the large ribosomal subunit.1 All
macrolides have a basic lactone ring with two or more amino
or neutral sugars attached to it. Commercially available
macrolides in Colombia include 14-membered (clarithromy-
cin and erythromycin) and 15-membered (azithromycin)
compounds.
Resistance to macrolides (such as erythromycin) and lin-
cosamides (such as clindamycin) is prevalent among Gram-
positive cocci.2—6 The most common resistance mechanisms
include: (1) ribosomal target modification by 23S rRNA
methylases encoded by the erm genes, and (2) active efflux
mediated by two classes of pumps: Msr(A), belonging to the
ATP-binding cassette (ABC) transporter superfamily and
Mef(A), a member of the major facilitator superfamily
(MFS).2—7 Methylase-mediated resistance also affects linco-
samides and type B streptogramins (MLSB-type of resis-
tance).2 Methylases are often harbored on transposons
(e.g., erm(A) on Tn554 and erm(B) on Tn551)8,9 or plasmids
(the erm(C) gene is usually located on small plasmids ranging
in size from 2.4 to 5 kb).10 MLSB-type of resistance can be
either constitutive (cMLSB) or inducible (iMLSB). These phe-
notypes can be identified in vitro by a disk diffusion test using
erythromycin (ERY) and clindamycin (CLI) disks (D-test).11
The iMLSB phenotype can be identified when a distorted (D-
shaped) zone of inhibition is observed around the CLI disk
when an ERY disk is placed nearby. It is widely accepted that
CLI should be used cautiously if organisms exhibit the iMLSB
type, since resistance to CLI may develop during therapy.3,12
Macrolide resistance in Gram-positive cocci has increased
dramatically all over the world13—16 and the use of these
antibiotics is unrestricted in Colombia. A particular concern
is the development of a high prevalence of resistance to
macrolides in pneumococci, since azithromycin continues to
be recommended for the treatment of respiratory infections
in Colombia (fluoroquinolones are less used due to financial
constraints). Moreover, Daneman et al. found that macrolide
resistance contributes to an increased risk of macrolide
failure in pneumococcal bacteremia, irrespective of the
underlying resistance mechanism or of the degree of eleva-
tion in erythromycin minimum inhibitory concentration
(MIC).17 Similarly, clindamycin is widely used in our country
(mostly without prescription) for the treatment of mild upper
respiratory and skin and soft tissue infections. Data on
macrolide or clindamycin resistance and their genetic deter-
minants are limited in Colombia.
This study was designed to perform phenotypic and geno-
typic characterization of a collection of macrolide-resistant
Gram-positive cocci from Colombian hospitals recovered in
specific countrywide surveillance programs from 1995 to
2004.Materials and methods
Bacterial isolates
Streptococcus pneumoniae
A total of 1679 clinical isolates were investigated for the
presence of macrolide resistance. All isolates were recovered
from blood and cerebrospinal fluid. Isolate identification was
performed by conventional laboratory tests such as suscept-
ibility to optochin and bile solubility.18 Quellung serotyping
and susceptibility to penicillin, trimethoprim—sulfamethox-
azole, ceftriaxone, chloramphenicol, erythromycin, and tet-
racycline were carried out on all isolates using the broth
microdilution method and following the National Committee
for Clinical Laboratory Standards/Clinical and Laboratory
Standards Institute (NCCLS/CLSI) methodology.19 Erythromy-
cin susceptibilities (using the same methodology) were
repeated if the organism was found to be resistant. Pneu-
mococcal isolates with well characterized mechanisms of
resistance were included as controls for PCR assays (see
below): an isolate with the M phenotype (harboring the
mef(A) gene) and a S. pneumoniae with the cMLSB-type of
resistance (carrying the erm(B) gene) were both kindly sup-
plied by Marguerite Lovgren from the Canadian National
Centre for Streptococcus. Only 55 erythromycin-resistant
invasive S. pneumoniae were identified between 1995 and
2004 (12.6% and 20.7% exhibited intermediate and high level
resistance to penicillin, respectively).
Staphylococci and enterococci
A collection of 348 isolates of S. aureus, 175 coagulase-
negative staphylococci (CoNS), and 123 enterococci recov-
ered during a 3-year period (2001—2003) in tertiary care
hospitals from Bogota´, Cali, Medellı´n, Cartagena, Neiva,
Monterı´a and Bucaramanga (seven major Colombian cities
with populations ranging from ca. 1 to 8 million inhabitants)
were included in this study.20,21 These isolates were recov-
ered from the following clinical samples: surgical wounds,
blood, abdominal abscesses, fluid from infected joints, peri-
toneal fluid, bronchoalveolar lavage (BAL), pleural effusion,
urine, cerebrospinal fluid, and skull abscesses from individual
patients in different wards. Isolates excluded from the study
included duplicate organisms from the same patient and
those recovered from sputum, catheters or skin (unless
originating in an infected surgical wound).20,21 Frozen stocks
were recovered, and culture purity and identification was
confirmed by standard biochemical methods and PCR.20,22
Genotyping by pulsed field gel electrophoresis (PFGE) for
methicillin-resistant Staphylococcus aureus (MRSA) and gly-
copeptide-resistant enterococci (GRE) were carried out pre-
viously in others studies. The results indicated that all
isolates were closely related.20,21,23
Antimicrobial susceptibility testing
Erythromycin was purchased from ICN Biomedicals, Inc.
(Irvine, CA, USA) and clindamycin was obtained from Pfizer
Inc. (New York, NY, USA). Susceptibility testing was per-
formed by broth microdilution method using cation-adjusted
Mueller—Hinton (MH) II (BBL Microbiology Systems, Cockeys-
ville, MD, USA) according to NCCLS/CLSI recommended
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against S. pneumoniae, staphylococci, and enterococci. All
MIC determinations were carried out with the inclusion of
reference strains as controls: Streptococcus pneumoniae
ATCC 49619, Staphylococcus aureus ATCC 29213, and Enter-
ococcus faecalis ATCC 29212.
Erythromycin—clindamycin double disk (ECDD)
test in staphylococci and Streptococcus
pneumoniae
The ECDD test was carried out following the recommendations
of Montanari et al. with minor modifications.24 For staphylo-
cocci and S. pneumoniae, ERY and CLI disks (15 and 2 mg,
respectively; BBL Microbiology Systems) were placed 15 mm
apart on a Mueller—Hinton agar (BBL Microbiology Systems)
plate.Mueller—Hintonagar supplementedwith5%sheepblood
was used for S. pneumoniae isolates. The plates were inocu-
lated with a swab dipped into a bacterial suspension corre-
sponding to a turbidity of 0.5 McFarland. After 18 h ofTable 1 Phenotypic and genotypic characteristics of 55 erythrom
MIC to ERY
mg/ml (n)
Phenotype
(n)
Serotype
(n)
Resistance to oth
antibiotics (n)
0.5 (2) M (1) 5 (1) CHL, TET
cMLSB (1) 6B (1) PEN-I, CLI
1.0 (53) cMLSB (15) 6B (14) PEN-I (1), PEN-R
CHL, SXT, TET, CL
23F (1) PEN-R, CRO, CHL
cMLSB (8) 14 (6) PEN-R, CRO, SXT,
6A (1)
19A (1)
cMLSB (3) 6B (3) PEN-R, CRO, CHL
M (1) 19F (1) PEN-R, CRO, CHL
cMLSB (1) 6B (1) PEN-I, CHL, SXT,
M (1) 19F (1) PEN-R, CHL, SXT,
cMLSB (1) 14 (1) PEN-I, SXT, TET, C
M (1) 19F (1) PEN-I, CRO, SXT,
cMLSB (1) 6B (1) PEN-I, CRO, SXT,
cMLSB (2) 6B (2) PEN-R, SXT, CLI
M (1) 14 (1) PEN-I, CRO, SXT
iMLSB (1) 14 (1) PEN-R, SXT, TET
M (1) 6B (1) PEN-I, CHL, SXT
M (1) 14 (1) PEN-R, SXT, TET
cMLSB (2) 6B (1) SXT, TET, CLI (2)
28A (1)
cMLSB (1) 14 (1) CHL, TET, CLI
cMLSB (3) 6B (1) TET, CLI (3)
14 (1)
6A (1)
M (1) 6A (1) PEN-I, SXT
cMLSB (1) 9V (1) CHL, CLI
M (4) 6A (4) PEN-I
iMLSB (1) 6B (1) TET
M (1) 21 (1) SXT
iMLSB (1) 1(1) None
MIC, minimum inhibitory concentration; ERY, erythromycin; PEN-I, int
resistance to penicillin; CRO, ceftriaxone; SXT, trimethoprim—sulfame
mycin. M, iMLSB and cMLSB refer to phenotypes of resistance (see text). B
clonally related.incubation at 37 8C, the absence of a zone of inhibition around
the two disks indicated constitutive resistance (cMLSB pheno-
type); blunting (D-shaped) of the clindamycin zone of inhibi-
tion proximal to the erythromycin disk indicated inducible
resistance (iMLSB phenotype) and susceptibility to clindamycin
with no blunting of the zone of inhibition around the clinda-
mycin disk was indicative of the M phenotype.
Molecular methods
Detection of erythromycin resistance genes
The presence of erythromycin resistance genes was deter-
mined by PCR. Primer sequences targeting the erm(A),
erm(B), erm(C) (encoding methylases), mef(A) and msr(A)
(encoding efflux pumps) genes were utilized according to the
recommendations of Martineau et al.22 and Sutcliffe et al.25
DNA preparation, amplification, and electrophoresis of PCR
products was carried out by standard procedures.22,25 S.
aureus ATCC 29213, 43300 and E. faecalis ATCC 29212 were
used as controls for all PCR assays.ycin-resistant Streptococcus pneumoniae
er Gene detected Clone (n)
mef(A) Colombia5-19 (1)
erm(B) NR (1)
(13), CRO,
I
erm(B) Spain6B-2 (14)
, SXT, TET, CLI erm(B) Spain23F-1 (1)
TET, CLI (8) erm(B) Spain9V-3 (3), NR (3)
erm(B) NR (1)
erm(B) NR (1)
, SXT, CLI erm(B) Spain6B-2 (3)
, SXT, TET mef(A) NR (1)
TET, CLI erm(B) Spain6B-2 (1)
TET mef(A) NR (1)
LI erm(B) NR (1)
TET mef(A) NR (1)
CLI erm(B) NR (1)
erm(B) NR (2)
mef(A) Spain9V-3 (1)
None NR (1)
mef(A) NR (1)
mef(A) NR (1)
erm(B) NR (1)
erm(B) NR (1)
erm(B) NR (1)
erm(B) NR (1)
erm(B) NR (1)
erm(B) NR (1)
mef(A) NR (1)
erm(B) NR (1)
mef(A) NR (4)
erm(B) NR (1)
mef(A) NR (1)
None NR (1)
ermediate levels of resistance to penicillin; PEN-R, high levels of
thoxazole; TET, tetracycline; CHL, chloramphenicol; CLI, clinda-
reakpoints of ERY for S. pneumoniae: S:0.25, I: 0.5, R:1. NR, not
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resistant Streptococcus pneumoniae isolates
SmaI macro-restriction fragment patterns were analyzed by
PFGE as described previously.26,27 Briefly, the chromosomal
DNA was digested with 20 U of SmaI Promega (Madison, WI,
USA) and PFGE was performed with a CHEF DR-II apparatus
(Bio-Rad Laboratories, Hercules, CA, USA). The assay para-
meters were as follows: initial pulse, 1 s; final pulse, 30 s;
voltage, 6 V/cm for 23 h; and temperature, 11.3 8C. Control
strains included S. pneumoniae R6 and international clones
Spain23F-1, Spain6B-2, Spain9V-3, and Colombia23F-26, which
are the most common clones circulating in Colombia.25 The
PFGE patterns were analyzed visually and interpreted
according to the criteria of Tenover et al.28 The computer
program Diversity 2.0 (Bio-Rad Laboratories) was used to
determine the genetic relationship of the isolates.
Results
Streptococcus pneumoniae
The prevalence of ERY and CLI resistance was 3.3% (55
isolates) and 2.3% (39 isolates), respectively. Amongst the
ERY-resistant isolates, 35 (63.6%) were from children and 20
(36.4%) from adults. A sub-analysis by year of all ERY-resistant
isolates indicated that macrolide resistance increased from
1.8% in 1994 to 5.3% in 2004 in isolates from children, and
from 2.9% (1994) to 3.5% (2004) in isolates from adults.
The majority of isolates (96.4%) had ERY MIC of 1.0 mg/
ml (Table 1). Two isolates (3.6%) were found to have inter-
mediate resistance (MIC 0.5 mg/ml). Both ERY MIC90 and CLI
MIC90 for S. pneumoniae were 32 mg/ml. Among the 55 ERY-Table 2 Phenotypic and genotypic characteristics of 523 Colomb
Organism (n) MIC to ERY mg/ml (n)
MSSA (140) 0.5 (132)
1—4 (0)
8 (8)
MRSA (208) 0.5 (13)
1—4 (0)
8 (195)
CoNS (175) 0.5 (64)
1—4 (0)
8 (111)
MIC, minimum inhibitory concentration; ERY, erythromycin; MSSA, m
resistant Staphylococcus aureus; CoNS, coagulase-negative staphylococresistant isolates, 38 (69.1%) were also fully resistant to CLI
(MIC 1.0 mg/ml) and one (1.8%) isolate was intermediate
(0.5 mg/ml). These 39 (70.9%) isolates exhibited the cMLSB
phenotype and harbored the erm(B) gene. Sixteen (29.1%)
isolates were found to be CLI susceptible (MIC<0.25 mg/ml):
three (5.5%) had the iMLSB phenotype and 13 (23.6%) were
found to have the M phenotype (Table 1). Amongst the three
isolates with iMLSB, one had the erm(B) gene and no gene was
detected in the remaining two. All 13 isolates with the M
phenotype carried the mef(A) gene. No isolate was found to
carry more than one macrolide resistance gene. Fifty-four
(98.2%) out of the 55 ERY-isolates were also intermediate or
fully resistant to one or more classes of antimicrobial agents
other than macrolides (Table 1).
Results from PFGE indicated that there was heterogeneity
in the population genetics of macrolide-resistant pneumo-
cocci. Amongst isolates with cMLSB-type of resistance (carry-
ing the erm(B) gene), 18 (46.2%) belonged to the Spain6B-2
clone, three (7.7%) to the Spain9V-3 clone, one (2.6%) to the
Spain23F-1 clone, and 17 (43.6%) were not related to any
international clones (Table 1). PFGE analysis of isolates with
the M phenotype indicated that 11 (84.6%) were not related
to international clones; one isolate belonged to the Colom-
bia5-19 clone and the remaining one to the Spain9V-3 clone.
The three isolates with iMLSB type of resistance did not show
a pattern related to any of the international pneumococcal
clones described so far (Table 1).
Staphylococcus aureus
The prevalence of ERYand CLI resistance in S. aureuswas 58%
and 57%, respectively. MRSA isolates exhibited higher resis-ian staphylococci
Phenotype (n) Gene detected (n)
None (132) None (132)
iMLSB (3) erm(A) (4)
cMLSB (1)
cMLSB (2) erm(C) (2)
M (2) msr(A) (2)
None (13) None (13)
cMLSB (153) erm(A) (153)
cMLSB (38) erm(C) (38)
cMLSB (4) erm(A) + msr(A) (4)
None (64) None (64)
cMLSB (10) erm(A) (10)
cMLSB (60) erm(C) (70)
iMLSB (10)
M (18) msr(A) (18)
cMLSB (1) erm(A) + msr(A) (2)
iMLSB (1)
cMLSB (8) erm(C) + msr(A) (11)
iMLSB (1)
M (2)
ethicillin-susceptible Staphylococcus aureus; MRSA, methicillin-
ci. M, iMLSB, and cMLSB refer to phenotypes of resistance (see text).
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cus aureus (MSSA) (94% vs. 5.7%, respectively) (Table 2). ERY
MIC90s for MRSA and MSSA were 64 and 0.5 mg/ml, respec-
tively and CLI MIC90s were 16 and 0.25 mg/ml for MRSA and
MSSA, respectively. Amongst the 195 ERY-resistant MRSA, all
isolates (100%) had the cMLSB phenotype and 153 carried the
erm(A) gene and 38 the erm(C) gene. Four isolates had a
combination of erm(A) plus msr(A) genes with MIC for ERY
64 mg/ml and MIC for CLI 16 mg/ml (Table 2).
Coagulase-negative staphylococci
Resistance to ERY and CLI was 63.4% and 45.1%, respectively.
The majority of isolates had MIC >64 mg/ml for ERY (80.2%)
and >32 mg/ml for CLI (70.3%). High resistance rates were
found to ERY (78.6%) and CLI (60.7%) in 90 methicillin-resis-
tant Staphylococcus epidermidis (MRSE) isolates. The most
frequent phenotype characterized was the cMLSB (71.2% of
isolates) (Table 2). The iMLSB and M phenotypes were less
common (10.8% and 18%, respectively). By PCR, these iso-
lates harbored the erm(C) gene (63.1%), erm(A) (9%) or
msr(A) (16.2%) genes, or combinations: erm(A) plus msr(A)
(1.8%) and erm(C) plus msr(A) (9.9%) (Table 2).
Enterococci
As expected, the majority of isolates exhibited MICs for ERY
128 mg/ml (62% for E. faecalis and 82% for Enterococcus
faecium). All enterococcal isolates with high level resistance
to ERY carried the erm(B) gene. No isolate was found to
harbor the mef(A) gene.
Discussion
Several surveillance programs on antimicrobial resistance
have been initiated in Colombia in the last few years directed
at specific Gram-positive microorganisms. In 1994, a Pan-
American Health Organization (PAHO) initiative funded by
the Canadian International Development Agency included
Colombia as part of an international survey (SIREVA-Vigia
project) designed to study S. pneumoniae invasive isolates
recovered from blood, cerebrospinal fluid (CSF), or any other
normal sterile body. The surveillance system included chil-
dren up to the age of 6 years with invasive disease.29,30
Subsequently the program has been extended to include
isolates from adults.31 Also, a systematic multicenter sur-
veillance of antimicrobial resistance in enterococci and sta-
phylococci has recently been carried out.20,21 The study of
such a collection of isolates, recovered under specific pro-
tocols, has allowed the characterization of resistance deter-
minants to several antibiotics and a better understanding of
the molecular epidemiology of particular microorganisms in
our country.
According to the SENTRY program, the percentage of
macrolide resistance in pneumococci was 13% for Colombia.32
However, only a single Colombian hospital was included, and
the minority of the isolates (13.1%) were contributed by
countries like Colombia, Mexico, Uruguay and Venezuela.
Argentina, Brazil and Chile contributed 86.9% of the iso-
lates.32 Our results clearly show that macrolide resistance
in pneumococci is much less than previously reported. It isintriguing that macrolide resistance in Colombia is still low in
spite of the unrestricted availability of these compounds. The
SIREVA project found that the rate of erythromycin resistance
in Colombia was only 4.7% (29/623) in isolates from bacterial
meningitis and acute respiratory infection between 1993 and
1999.33 Our study suggests that this trend is stable with an
overall rate of resistance of only 3% for invasive isolates and it
is probably a reflection of the type of antibiotic usage in
Colombia.33 In fact, rates of macrolide resistance are much
lower than in the USA, where an important increase in
macrolide resistance rates has been observed in the last
decade (10.3% in 1994 to 26.2% in 2000).34,35 Our situation
is also dramatically different from that of Asian countries.
Multinational surveillance programs of pneumococcal resis-
tance by the Asian Network for Surveillance of Resistant
Pathogens (ANSORP) during 1996—1997 documented very
high prevalence rates (>60%) of erythromycin resistance
among clinical isolates of S. pneumoniae in Taiwan, Korea,
Japan and Vietnam.13,36 Another surveillance study also
reported that Hong Kong and Japan showed an alarmingly
high prevalence of erythromycin resistance in pneumococci
(79.3% and 71.0%, respectively).37 A caveat when analyzing
those studies is that invasive and non-invasive isolates were
not clearly distinguished. Nonetheless, it has been shown
that invasive isolates have a higher prevalence of macrolide
resistance than non-invasive ones,6 supporting the fact that
the prevalence of macrolide resistance in invasive isolates
from Colombia is still lower than in other regions of the
world. Another interesting aspect is that an important
increase in the rates of penicillin resistance has been
observed in Colombian pneumococci,30 suggesting that b-
lactams are perhaps the preferred antibiotic to treat respira-
tory infections. In fact, the daily cost of amoxicillin in
Colombia (generic compound) for a respiratory infection
would be about US$0.50 compared to US$1.50 for generic
azithromycin.
Our findings also indicate that among the erythromycin-
resistant S. pneumoniae isolates, the most common macro-
lide resistance mechanism is mediated by the erm(B) gene
(among isolates with the cMLSB phenotype). This mechanism
of resistance is predominant among macrolide-resistant
pneumococci from most European countries,38 and it is the
most common mechanism of erythromycin resistance in
Korea, China, Taiwan and Sri Lanka.13,39 In contrast, the
mef(A)-mediated efflux mechanism is more frequent in ery-
thromycin-resistant S. pneumoniae from North America and
Chile.40,41 We were unable to detect either the mef(A) or
erm(ABC) genes in two isolates of pneumococci that exhib-
ited macrolide resistance phenotypically (iMLSB-type). It is
likely that sequence variation at the erm (or mef) locus or a
different erm or mef-like gene might be present in these
isolates. Other mechanisms of resistance, such as alteration
of the ribosomal target site via mutations are also possible.42
In numerous studies, penicillin, macrolide, or multidrug
resistance have been linked to specific serotypes.43,44 In
central Italy, serotypes 6 and 19 had far higher rates of
resistance to erythromycin than other serotypes.45 Isolates
carrying the erm(B) (erm(AM)) gene are most often observed
within serotypes 6B, 23F, 14 or 19F whereas mef(E) isolates
are associated with serotypes 14, 6A, or 19F.43 A recent study,
using PFGE has shown that erythromycin-resistant S. pneu-
moniae isolates containing both erm(B) and mef(A) in Korea
334 J. Reyes et al.are identical to the Taiwan19F-14 clone.39 Our study found an
important association between S. pneumoniae serotype 6B
erythromycin-resistant isolates and the Spain6B-2 clone. This
particular clone has been circulating in our country since
1994.27
The overall rates of ERYand CLI resistance for S. aureus in
our study were 58% and 57%, respectively, which are signifi-
cantly higher than in other parts of the world with a clear
difference between MSSA and MRSA (5.7% vs. 94%, respec-
tively).14,15 With respect to MRSA, recent data suggest that
an important shift in the population genetics of Colombian
MRSA has occurred in the last few years.21 A single dominant
clone that was prevalent in 1996—1998 (designated ‘pedia-
tric’ clone) has been replaced by a new PFGE clone.21 The
new electrophoretic type (designated type F), was originally
isolated in Chile.21 The situation clearly differs from the rest
of South America where the Brazilian clone predominates. In
terms of antimicrobial resistance, isolates belonging to this
clone exhibited high rates of resistance to ERY and CLI. Our
findings confirm that the majority of these isolates have the
cMLSB phenotype and carry the erm(A) (the majority) or
erm(C) genes. Clindamycin is one of the therapeutic options
in the treatment of MRSA;46,47 it seems that this antibiotic is
not useful in the treatment of hospital-associated MRSA
infections in our country. It is not known if Colombian com-
munity-associated MRSA represent a different bacterial
population (as is the case in the USA).48,49
In CoNS, the erm(C) gene was commonly identified. These
results confirmed those of Eady et al.50 and Leclercq et al.,2
who documented the predominance of erm(C) in a large
series of clinical and commensal CoNS. Similarly, enterococci
harbored the erm(B) gene. It is clear that macrolides are not
therapeutic alternatives for the treatment of CoNS or enter-
ococcal infections. However, our findings support the fact
that a pool of macrolide-resistant genes is carried by these
two species and horizontal gene transfer could occur to other
Gram-positive organisms.
In conclusion, this is the first study aimed at characterizing
the phenotypic and genotypic characteristics of erythromy-
cin-resistant Gram-positive cocci isolates from Colombia.
The most prevalent phenotype amongst Colombian S. pneu-
moniae, S. aureus, CoNS, and enterococci was the cMLSB-
type mediated by the erm genes. Increases in resistance,
together with significant local differences in resistance pat-
terns,51 make results of local surveillance studies an impor-
tant tool to guide therapy and for judicious use of
antimicrobial agents.
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